肝病患者血浆cAMP、cGMP和ANP变化的意义探讨

Preliminary Studies on Plasma cAMP、cGMP and ANP in Hepatic Diseases

为了探讨肝病中ｃＡＭＰ、ｃＧＭＰ和ＡＮＰ的变化规律及其相互间的关系，本文用放射免疫法测定肝炎、代偿期和失代偿期肝硬化病人的血浆ｃＡＭＰ、ｃＧＭＰ和ＡＮＰ含量并与正常对照，发现肝炎组血浆ｃＡＭＰ与正常组比较无显著差异。ｃＡＭＰ／ｃＧＭＰ比值依次为肝炎组＞代偿期肝硬化＞失代偿期肝硬化。失代偿期肝硬化ｃＧＭＰ和ＡＮＰ显著高放正常和代偿期肝硬化。提示ｃＧＭＰ可能是ＡＮＰ的第二信使。ｃＡＭＰ／ｃＧＭＰ比值可作为肝病严重程度的判断指标。

The plasma cAMP in normal control(23.83±9.05 pmol/ml)was much higher than that of cGMP(4.63±0.92 pmol/ml). In patients with hepatitis cAMP showed no significant difference with normal control, due to too small a marker of acute cases. The ratio of cAMP was 4. 93 in normal controls,3. 06 in patients with hepatitis,1. 47 in compensatory cirrhotics,0. 98 in decompensatory cirrhotics, showing its value in evaluating the diseased serverity, In decompensatory cirrhotics, cGMP(21.11 ±7.09 pmol/ml)and ANP(1084.89 ±873.90 pg/ml) were higher than those in compensatory cirrhotics (15. 91±5. 69 pmol/ml、406.86±205.89 pg/ml respectively) ;and normal controls(4.83±0. 92 pmol/ml、176.83±59.25 pg/ml respectively ). This suggested cGMP could be a second messenger activating ANP